Protocol No
SWOG-S2114
Staff Member
Mehdi Hamadani
Phase
II
Summary
To find out if this approach is better or worse than the usual approach for DLBCL patients receiving CAR T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients is follow-up visits with no further therapy.
Objective
To find out if this approach is better or worse than the usual approach for DLBCL patients receiving CAR T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients is follow-up visits with no further therapy.
Study Sites
Moorland Reserve Health Center
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov